# A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

> **NCT06649162** · — · RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 10000 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06649162
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649162, "A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06649162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*